Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Pliant Therapeutics (PLRX) over the last 5 years, with Q3 2025 value amounting to 3468.59%.

  • Pliant Therapeutics' EBIT Margin changed N/A to 3468.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 7681.22%, marking a year-over-year change of. This contributed to the annual value of 11654.75% for FY2023, which is 103413800.0% down from last year.
  • Per Pliant Therapeutics' latest filing, its EBIT Margin stood at 3468.59% for Q3 2025.
  • Pliant Therapeutics' 5-year EBIT Margin high stood at 7376.1% for Q1 2025, and its period low was 19083.87% during Q2 2023.
  • In the last 4 years, Pliant Therapeutics' EBIT Margin had a median value of 1280.27% in 2021 and averaged 1378.83%.
  • As far as peak fluctuations go, Pliant Therapeutics' EBIT Margin surged by 6861200bps in 2022, and later plummeted by -184897200bps in 2023.
  • Pliant Therapeutics' EBIT Margin (Quarter) stood at 1230.57% in 2021, then tumbled by -55bps to 1903.31% in 2022, then plummeted by -903bps to 19083.87% in 2023, then skyrocketed by 118bps to 3468.59% in 2025.
  • Its EBIT Margin stands at 3468.59% for Q3 2025, versus 5635.6% for Q2 2025 and 7376.1% for Q1 2025.